PIRS News and Press, Pieris Pharmaceuticals Inc. From 03/29/23

2023-03-29 15:40:06 ET Pieris Pharmaceuticals, Inc. (PIRS) Q4 2022 Results Earnings Conference Call March 29, 2023, 08:00 AM ET Company Participants Thomas Bures - Senior Vice President and Chief Financial Officer Stephen Yoder - President and Chief Executive Officer...

2023-03-29 11:04:07 ET Pieris Pharmaceuticals ( NASDAQ: PIRS ) stock fell ~17% on Wednesday after the company's mixed FY22 results. Net loss narrowed to -$33.28M, compared to -$45.74M in 2021. Meanwhile, full year 2022 revenue declined -17.5% Y/Y to $25.9M. "Pi...

2023-03-29 10:05:07 ET Gainers: Kodiak Sciences ( KOD ) +19% . Arcturus Therapeutics ( ARCT ) +16% . Erasca ( ERAS ) +15% . G Medical Innovations ( GMVD ) +15% . Atai Life Sciences ( ATAI ) +13% . Losers: ProQR The...

2023-03-29 08:23:45 ET Draganfly DPRO -17% on proposed securities offering . SomaLogic SLGC -15% on Q4 earnings release . Shift Technologies SFT -15% on Q4 earnings release . Sharecare SHCR -12% on Q4 earnings release . Allarity Therapeu...

2023-03-29 07:05:41 ET Pieris Pharmaceuticals press release ( NASDAQ: PIRS ): FY GAAP EPS of -$0.45 beats by $0.02 . Revenue of $25.9M (-17.5% Y/Y) misses by $0.67M . Cash, cash equivalents, and investments totaled $59.2 million for the year ended December 31, ...

COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MARCH 29, 2023, AT 8:00 AM EDT Continued advancement of pipeline, including two clinical-stage inhaled respiratory programs and additional therapeutic programs for serious diseases Elarekibep (PRS-060/AZD1402) Phase 2a study...

2023-03-28 14:23:38 ET Pieris Pharmaceuticals ( NASDAQ: PIRS ) is scheduled to announce Q4 earnings results on Wednesday, March 29th, before market open. The consensus EPS Estimate is -$0.13 and the consensus Revenue Estimate is $6.51M For further details see: Pi...

BOSTON, MA / ACCESSWIRE / March 24, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) ,a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced tha...

Boston-based Pieris Pharmaceuticals ( NASDAQ: PIRS ) said it achieved a $5M milestone from Seagen after the Bothell, Wash.-based company dosed the first patient in a phase 1 trial of cancer drug SGN-BB228 (PRS-346). The Seagen-sponsored phase 1 study is evaluating the sa...

BOSTON, MA / ACCESSWIRE / January 10, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other conditions, today announ...